^
Association details:
| Biomarker: | FER overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Regimen: | TAC (cyclophosphamide + docetaxel + doxorubicin hydrochloride) |
| Direction: | Resistant |
Evidence:
Source:
Title:
FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer
Published date:
04/05/2022
Excerpt:
We analyzed gene expression data from the MATADOR study (van Rossum et al., 2018
), a randomized phase III clinical trial in which 664 patients were treated with either adjuvant dose-dense doxorubicin + cyclophosphamide (ddAC) or AC combined with docetaxel (TAC)...high FER levels correlated with an increased probability of recurrence-free survival (RFS) following taxane-containing treatment, compared with ddAC-only treatment (adjHR = 0.48; 95% CI: 0.24–0.96; p = 0.039) (Figure 2E).
DOI:
10.1016/j.celrep.2022.110584
